Guide Appropriate DOAC Use in Special Populations
November 2026
Using direct oral anticoagulants (DOACs) isn’t as cut-and-dried in special populations...patients with kidney disease, obesity, etc.
Account for comorbidities when helping teams pick a DOAC for stroke prevention in atrial fib, thromboembolism prophylaxis or treatment, etc.
Chronic kidney disease (CKD). Know that all DOACs are generally safe down to Stage 4 CKD (eGFR 15-30 mL/min). But check drug labeling for dose reductions (dabigatran 75 mg bid, edoxaban 30 mg daily, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote